PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

a16z Bio + Health Fund

Menlo Park, CAA16Z-BIO-HEALTH-FUND
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Andreessen Horowitz's fund at the convergence of biology and technology.

Classification
Sluga16z-bio-health-fund
HQMenlo Park, CA
Stage FocusPrimarily Series A and B in digital health and biotech, t…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

This is a16z trying to buy their way into healthcare credibility, and it's actually working pretty well. The partners are solid — Vineeta knows her stuff technically, Julie has real operator experience, and they're building a legitimate healthcare network. They move fast when they want something and can write big checks, but you're getting the full a16z treatment: high expectations, lots of portfolio company cross-pollination, and pressure to think big. The flip side is they sometimes push companies to scale too aggressively before product-market fit is locked in. If you want maximum acceleration and can handle the intensity, they're legit.

KEY TAKEAWAYS
  • Best for: Technical founders who want to scale fast with serious capital
  • Watch out for: Pressure to grow before PMF is solid
  • Known for: Strong technical diligence and healthcare network effects
Investment Thesis

a16z Bio + Health invests in companies using technology to transform healthcare and life sciences. They focus on digital health, biotech, medical devices, and healthcare infrastructure with particular interest in AI/ML applications in biology and medicine.

Stage & Sector Focus

Primarily Series A and B in digital health and biotech, though they'll go earlier for exceptional teams. Heavy focus on AI-driven drug discovery, precision medicine, and healthcare infrastructure plays. Less consumer health apps, more enterprise and pharma-facing solutions.

Notable Portfolio
FreenomeMindstrongDevoted HealthRoTempusColor GenomicsNurxStrive Health
Key Partners
Vineeta Agarwala
General Partner

Former Google product manager and physician-scientist. Strong technical background in computational biology and healthcare AI. Known for being deeply technical and hands-on with portfolio companies on product strategy.

Julie Yoo
General Partner

Co-founder of Kyruus (healthcare software) before joining a16z. Has operational experience scaling healthcare companies and is well-regarded for her network in digital health. Founders say she's practical and execution-focused.

Daisy Wolf
Partner

Former McKinsey healthcare consultant who joined a16z early in her investing career. Focuses on healthcare services and infrastructure. Still building her reputation but getting positive founder feedback for being responsive and thoughtful.

Have a specific question about a16z Bio + Health Fund?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1